Updated 07:15 GMT, 18 Nov 2026 SPX 7,340.53 -1.03% NDX 27,001.78 -0.72% VIX 25.46 +11.13% GOLD 3,772.20 -2.38% CL 83.98 -2.36% BTC 64,721.99 -0.26%
NAS100 27,002 −0.72% S&P 7,341 −1.03% GOLD $3,772 −2.38% BTC $64,722 −0.26% VIX 25.46 +11.13% latest tape · as of 07:15 UTC
The Screen · Healthcare · Medical Devices

Inspire Medical Systems, Inc. logoInspire Medical Systems, Inc.

INSP · the NYSE · USD · Market cap $1.9B · 1,333 employees

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and inter…

PASS · Titan Ethical · score 70.0
59.41 USD

Price as of 17 Nov 2026Daily close, not a live quote

Screened 2026-11-17 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price59.41 USD at the 17 Nov 2026 close
  • Our value readOvervalued vs our fair value, as of 17 Nov 2026
  • Our regime readMarkdown, as of 16 Nov 2026
  • Ethical screenPasses, score 70.0 out of 100
  • OptionsOpen interest leans to puts (put/call 1.11)
  • Last reviewed17 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $36.00 to $47.70, base estimate $41.48 (screen dated 2026-11-17).

Current read
Markdown ?
Overvalued · screened 2026-11-17
  • Trend Markdown
  • Insiders no filings inside 60 days, left as found
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.11, read 2026-11-17
  • Ethical passes the values gate
Price59.41 USD
Fair value41.48
Ethical score70.0/100
Value readOvervaluedas of 17 Nov 2026
Our investment reviews on this name
2026-11-16Read Markdown61.10-2.8% to today ✓Markup gives way to Markdown first Markdown read since October
2026-11-09Read Markup63.98-7.1% to today Accumulation gives way to Markup after a 6% slide in 9 days
2026-10-31Read Accumulation68.10-12.8% to today Markdown gives way to Accumulation
2026-10-29Read Markdown70.97-16.3% to today ✓Accumulation gives way to Markdown with volume flow in agreement

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markdown label.

Inspire Medical Systems, Inc. holds its Markdown at $59.41. Consolidating, no directional conviction, held for 47 days.

As held on the ledger · 2026-11-17
PhaseMarkdown · caution
Quantitative stateConsolidating, no directional conviction, held for 47 days
Price at the screen$59.41
Valuation19.86 trailing · 44.49 forward price to earnings
Values screenPASS · score 70.0
Beta0.65
The Workings

Five Screens, Shown in Full

Full pass across all five screens. This security clears the Titan Ethical Standard: its business and its balance sheet both stay inside the lines.

TestFigureLimitWhat it meansStatus
Business activity Permissible Core business clean Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
Debt load 3.54% Below 33% Interest-bearing debt is just 3.5% of its assets, well under the one-third ceiling: it does not run on borrowed money. Pass
Interest-bearing cash 10.62% Below 33% Cash held in interest-bearing accounts and securities is 10.6% of assets, under the one-third limit. Pass
Receivables 24.74% Below 49% Money owed to the company is 24.7% of assets, under the 49% limit. Pass
Revenue purity 1.92% Below 5% Only 1.9% of revenue comes from non-compliant sources, under the 5% line. Pass

Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.

The Ethical Read

Why It Clears, in Plain English

Inspire Medical Systems, clears all five screens. Its business is in a permissible area, its interest-bearing debt is about 4%, inside the ~33% line, and interest is about 2% of its income, under the ~5% line, so it passes.

Read as at 2026-11-17. It updates when the underlying figures move, and past reads are kept below.

Follow this verdict

Get an email when INSP's ethical verdict changes

Today INSP passes the screen. If new figures move it to a fail, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Overvalued vs our fair value, as of 17 Nov 2026: it trades above our $41.48 fair value estimate.

How a fair value is estimated: discounted cash flow (DCF).

36.00Conservative41.48Base case47.70Growth case 59.41Price

Fair value range in USD, drawn from the 2026-11-17 screen. The gold marker is the market price at the same screen. The price runs 43.2% above the base estimate.

The Street's Range
40.00Street low 69.50Street average 97.00Street high 59.41Price

Third-party analyst targets: 16 covering, consensus Hold. The average target sits +17% from the screen price.

Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.

Price History & Projections

Where our models see it going: fair-value estimate $41.48, with a range of $36.00 to $47.70, dated to the 2026-11-17 screen.

Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.

The Business, in Plain Words

Why it gives us pause

At 44.5x forward earnings, the price already runs ahead of the business. It trades 43% above our $41.48 fair value, so you would be buying at a premium, not a discount.

The fundamentals · plain-English read
Forward P/E44.5xexpensive: the price assumes strong growth ahead
Trailing P/E19.9xreasonably valued
EPS, trailing3.35
EPS, forward1.50
Revenue growth-7.9%revenue is shrinking
Profit margin11.4%thin but positive margins
Return on equity13.5%a solid return on shareholder capital
FCF yield3.96%
Debt to equity3.46heavy leverage: higher risk if revenue softens
Current ratio6.45comfortably covers its short-term bills
Beta0.65steadier than the market
Short interest, float0.20%
52-week range38.91 - 147.03
Market cap$1.9B
Employees1,333

Another profit measure, before interest, tax and non-cash costs: EBITDA.

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; it carries a real debt load, which raises the stakes if revenue slips.

Plain-English interpretation of our own screen data. Analysis, not advice.

Where & How to Trade

INSP trades on the NYSE. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-16 Markdown · changed $61.10 -4.5% Entry 19

The framework has shifted from markup to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 4.5% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52.

2026-11-09 Markup · changed $63.98 -6.0% Entry 18

The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 6.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading bearish. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52.

2026-11-02 Accumulation $68.10 +0.0% Entry 17

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-11-01 Accumulation $68.10 +0.0% Entry 16

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-31 Accumulation · changed $68.10 -4.0% Entry 15

The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 4.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-30 Markdown $70.97 +0.0% Entry 14

The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-29 Markdown · changed $70.97 -2.3% Entry 13

The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 2.3% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-28 Accumulation $72.66 +0.0% Entry 12

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-27 Accumulation $72.66 +0.0% Entry 11

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

2026-10-26 Accumulation $72.66 +0.0% Entry 10

The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is momentum reading neutral. Over the past year the shares are down 69%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (12 analysts) rates it hold, with a mean price target of $52. It reported earnings in this window, a natural checkpoint for the thesis.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

Latest News · What the Market Is Reading on INSP

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in INSP's Space

Screened names in the same industry · explore each on its own page.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $43.35 -2.8% · $972 -2.8%
2 months $54.02 -22.0% · $780 -22.0%
3 months $58.25 -27.6% · $724 -27.6%
6 months $137.37 -69.3% · $307 -69.3%
1 year $136.73 -69.2% · $308 -69.2%
2 years $160.97 -73.8% · $262 -73.8%
3 years $307.00 -86.3% · $137 -86.3%
5 years $183.10 -77.0% · $230 -77.0%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever INSP does next, these words stay.

Inspire Medical Systems, Inc. · INSP · Markdown · $59.41
Recorded 2026-11-17 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.